Plasma Fatty Acids in Chronic Kidney Disease: Nervonic Acid Predicts Mortality

Journal of Renal Nutrition

Volumn 22, Issue 2, 2012, Pages 277-283

  Shearer, Gregory C ^a   Carrero, Juan J ^b   Heimbürger, Olof ^b   Barany, Peter ^b   Stenvinkel, Peter ^b  

^a SANFORD RESEARCH   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

15 TETRACOSENOIC ACID; FATTY ACID; MONOUNSATURATED FATTY ACID;

AGED; ARTICLE; BLOOD; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY FAILURE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; MIDDLE AGED; MORTALITY; PILOT STUDY; PROSPECTIVE STUDY; RENAL REPLACEMENT THERAPY; RISK FACTOR;

AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; FATTY ACIDS; FATTY ACIDS, MONOUNSATURATED; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE, CHRONIC; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; RENAL DIALYSIS; RISK FACTORS;

EID: 84857362302     PISSN: 10512276     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jrn.2011.05.005     Document Type: Article

References (32)

1. Keith D.S., Nichols G.A., Gullion C.M., et al. Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 2004, 164:659-663.
2. Trivedi H.S., Pang M.M., Campbell A., et al. Slowing the progression of chronic renal failure: economic benefits and patients' perspectives. Am J Kidney Dis 2002, 39:721-729.
3. Stenvinkel P. Chronic kidney disease: a public health priority and harbinger of premature cardiovascular disease. J Intern Med 2010, 268:456-467.
4. Stenvinkel P., Carrero J.J., Axelsson J., et al. Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle?. Clin J Am Soc Nephrol 2008, 3:505-521.
5. Lloyd-Jones D.M., Liu K., Tian L., et al. Narrative review: assessment of C-reactive protein in risk prediction for cardiovascular disease. Ann Intern Med 2006, 145:35-42.
6. Folsom A.R., Chambless L.E., Ballantyne C.M., et al. An assessment of incremental coronary risk prediction using C-reactive protein and other novel risk markers: the atherosclerosis risk in communities study. Arch Intern Med 2006, 166:1368-1373.
7. Carrero J.J., Stenvinkel P. Inflammation in end-stage renal disease-what have we learned in 10 years?. Semin Dial 2010, 23:498-509.
8. Chmielewski M., Carrero J.J., Nordfors L., et al. Lipid disorders in chronic kidney disease: reverse epidemiology and therapeutic approach. J Nephrol 2008, 21:635-644.
9. Kalantar-Zadeh K., Block G., Humphreys M.H., et al. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int 2003, 63:793-808.
10. Carrero J.J., Stenvinkel P. Persistent inflammation as a catalyst for other risk factors in chronic kidney disease: a hypothesis proposal. Clin J Am Soc Nephrol 2009, 4(suppl 1):S49-S55.
11. Kovesdy C.P., Anderson J.E. Reverse epidemiology in patients with chronic kidney disease who are not yet on dialysis. Semin Dial 2007, 20:566-569.
12. Shearer G.C., Pottala J.V., Spertus J.A., et al. Red blood cell fatty acid patterns and acute coronary syndrome. PLoS One 2009, 4:e5444.
13. Shearer G.C., Chen J., Chen Y., et al. Myocardial infarction does not affect fatty-acid profiles in rats. Prostaglandins Leukot Essent Fatty Acids 2009, 81:411-416.
14. Marchioli R., Barzi F., Bomba E., et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation 2002, 105:1897-1903.
15. Yokoyama M., Origasa H., Matsuzaki M., et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 2007, 369:1090-1098.
16. Tavazzi L., Maggioni A.P., Marchioli R., et al. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008, 372:1223-1230.
17. Tavazzi L., Maggioni A.P., Marchioli R., et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008, 372:1231-1239.
18. Donadio J.V., Larson T.S., Bergstralh E.J., et al. A randomized trial of high-dose compared with low-dose omega-3 fatty acids in severe IgA nephropathy. J Am Soc Nephrol 2001, 12:791-799.
19. Svensson M., Schmidt E.B., Jorgensen K.A., et al. N-3 fatty acids as secondary prevention against cardiovascular events in patients who undergo chronic hemodialysis: a randomized, placebo-controlled intervention trial. Clin J Am Soc Nephrol 2006, 1:780-786.
20. Friedman A.N., Moe S.M., Perkins S.M., et al. Fish consumption and omega-3 fatty acid status and determinants in long-term hemodialysis. Am J Kidney Dis 2006, 47:1064-1071.
21. Friedman A.N., Saha C., Watkins B.A. Feasibility study of erythrocyte long-chain omega-3 polyunsaturated fatty acid content and mortality risk in hemodialysis patients. J Ren Nutr 2008, 18:509-512.
22. Stenvinkel P., Heimburger O., Paultre F., et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 1999, 55:1899-1911.
23. Carrero J.J., Qureshi A.R., Axelsson J., et al. Comparison of nutritional and inflammatory markers in dialysis patients with reduced appetite. Am J Clin Nutr 2007, 85:695-701.
24. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002, 39:S1-S266.
25. Levey A.S., Bosch J.P., Lewis J.B., et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999, 130:461-470.
26. Harris W.S., Von Schacky C. The omega-3 index: a new risk factor for death from coronary heart disease?. Prev Med 2004, 39:212-220.
27. Guillou H., Zadravec D., Martin P.G., et al. The key roles of elongases and desaturases in mammalian fatty acid metabolism: insights from transgenic mice. Prog Lipid Res 2010, 49:186-199.
28. Ollero M., Laposata M., Zaman M.M., et al. Evidence of increased flux to n-6 docosapentaenoic acid in phospholipids of pancreas from cftr-/- knockout mice. Metabolism 2006, 55:1192-1200.
29. Kawashima A., Sugawara S., Okita M., et al. Plasma fatty acid composition, estimated desaturase activities, and intakes of energy and nutrient in Japanese men with abdominal obesity or metabolic syndrome. J Nutr Sci Vitaminol (Tokyo) 2009, 55:400-406.
30. Dolegowska B., Kwiatkowska E., Wesolowska T., et al. Effect of hemodialysis on the content of fatty acids in monolayers of erythrocyte membranes in patients with chronic renal failure. Ren Fail 2007, 29:447-452.
31. Jo S.K., Bajwa A., Awad A.S., et al. Sphingosine-1-phosphate receptors: biology and therapeutic potential in kidney disease. Kidney Int 2008, 73:1220-1230.
32. Friedman A.N., Siddiqui R., Watkins B.A. Acute rise of omega-3 polyunsaturated fatty acids during hemodialysis treatment. J Ren Nutr 2008, 18:301-303.